National Centre for Neuroimmunology and Emerging Diseases, Menzies Health Institute, Griffith University, Gold Coast, Australia.
School of Medical Science, Griffith University, Gold Coast, Australia.
Probiotics Antimicrob Proteins. 2018 Sep;10(3):466-477. doi: 10.1007/s12602-018-9397-8.
Gastrointestinal (GI) symptoms and irritable bowel (IB) symptoms have been associated with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). The aim of this study was to conduct a systematic review of these symptoms in CFS/ME, along with any evidence for probiotics as treatment. Pubmed, Scopus, Medline (EBSCOHost) and EMBASE databases were searched to source relevant studies for CFS/ME. The review included any studies examining GI symptoms, irritable bowel syndrome (IBS) and/or probiotic use. Studies were required to report criteria for CFS/ME and study design, intervention and outcome measures. Quality assessment was also completed to summarise the level of evidence available. A total of 3381 publications were returned using our search terms. Twenty-five studies were included in the review. Randomised control trials were the predominant study type (n = 24). Most of the studies identified examined the effect of probiotic supplementation on the improvement of IB symptoms in IBS patients, or IB symptoms in CFS/ME patients, as well as some other significant secondary outcomes (e.g. quality of life, other gastrointestinal symptoms, psychological symptoms). The level of evidence identified for the use of probiotics in IBS was excellent in quality; however, the evidence available for the use of probiotic interventions in CFS/ME was poor and limited. There is currently insufficient evidence for the use of probiotics in CFS/ME patients, despite probiotic interventions being useful in IBS. The studies pertaining to probiotic interventions in CFS/ME patients were limited and of poor quality overall. Standardisation of protocols and methodology in these studies is required.
胃肠道（GI）症状和肠易激（IB）症状与慢性疲劳综合征/肌痛性脑脊髓炎（CFS/ME）有关。本研究旨在对 CFS/ME 中的这些症状进行系统评价，并对益生菌作为治疗方法的任何证据进行评估。通过检索 Pubmed、Scopus、Medline（EBSCOHost）和 EMBASE 数据库，查找与 CFS/ME 相关的研究。本综述纳入了任何研究 GI 症状、肠易激综合征（IBS）和/或益生菌使用的研究。研究需要报告 CFS/ME 的标准以及研究设计、干预和结果测量。还进行了质量评估，以总结现有证据的水平。使用我们的搜索词共返回了 3381 篇出版物。25 项研究被纳入综述。随机对照试验是主要的研究类型（n=24）。大多数确定的研究都检查了益生菌补充剂对改善 IBS 患者的 IB 症状或 CFS/ME 患者的 IB 症状的影响，以及一些其他重要的次要结果（例如，生活质量、其他胃肠道症状、心理症状）。益生菌在 IBS 中使用的证据质量被认为是极好的；然而，在 CFS/ME 中使用益生菌干预的证据质量差且有限。尽管益生菌干预在 IBS 中有用，但目前仍缺乏在 CFS/ME 患者中使用益生菌的证据。与 CFS/ME 患者益生菌干预相关的研究有限，且总体质量较差。这些研究需要标准化方案和方法。
